Display options
Cite
Li M, Kang JW, Sukumar S, et al. Multiplexed detection of serological cancer markers with plasmon-enhanced Raman spectro-immunoassay. Chem Sci. 2015;6(7):3906-3914doi: 10.1039/C5SC01054C.
Li, M., Kang, J. W., Sukumar, S., Dasari, R. R., & Barman, I. (2015). Multiplexed detection of serological cancer markers with plasmon-enhanced Raman spectro-immunoassay. Chemical science, 6(7), 3906-3914. https://doi.org/10.1039/C5SC01054C
Li, Ming, et al. "Multiplexed detection of serological cancer markers with plasmon-enhanced Raman spectro-immunoassay." Chemical science vol. 6,7 (2015): 3906-3914. doi: https://doi.org/10.1039/C5SC01054C
Li M, Kang JW, Sukumar S, Dasari RR, Barman I. Multiplexed detection of serological cancer markers with plasmon-enhanced Raman spectro-immunoassay. Chem Sci. 2015 Jul 01;6(7):3906-3914. doi: 10.1039/C5SC01054C. PMID: 26405519; PMCID: PMC4577055.
Copy Download .nbib Format: NLM
Share it on

Chem Sci. 2015 Jul 01;6(7):3906-3914. doi: 10.1039/C5SC01054C.

Multiplexed detection of serological cancer markers with plasmon-enhanced Raman spectro-immunoassay.

Chemical science

Ming Li, Jeon Woong Kang, Saraswati Sukumar, Ramachandra Rao Dasari, Ishan Barman

Affiliations

  1. Department of Mechanical Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States ; Laser Biomedical Research Center, George R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
  2. Laser Biomedical Research Center, George R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
  3. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States.
  4. Department of Mechanical Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States ; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States.

PMID: 26405519 PMCID: PMC4577055 DOI: 10.1039/C5SC01054C

Abstract

Circulating biomarkers have emerged as promising non-invasive, real-time surrogates for cancer diagnosis, prognostication and monitoring of therapeutic response. Emerging data, however, suggest that single markers are inadequate in describing complex pathologic transformations. Architecting assays capable of parallel measurements of multiple biomarkers can help achieve the desired clinical sensitivity and specificity while conserving patient specimen and reducing turn-around time. Here we describe a plasmon-enhanced Raman spectroscopic assay featuring nanostructured biomolecular probes and spectroscopic imaging for multiplexed detection of disseminated breast cancer markers cancer antigen (CA) 15-3, CA 27-29 and cancer embryonic antigen (CEA). In the developed SERS assay, both the assay chip and surface-enhanced Raman spectroscopy (SERS) tags are functionalized with monoclonal antibodies against CA15-3, CA27-29 and CEA, respectively. Sequential addition of biomarkers and functionalized SERS tags onto the functionalized assay chip enable the specific recognition of these biomarkers through the antibody-antigen interactions, leading to a sandwich spectro-immunoassay. In addition to offering extensive multiplexing capability, our method provides higher sensitivity than conventional immunoassays and demonstrates exquisite specificity owing to selective formation of conjugated complexes and fingerprint spectra of the Raman reporter. We envision that clinical translation of this assay may further enable asymptomatic surveillance of cancer survivors and speedy assessment of treatment benefit through a simple blood test.

References

  1. ACS Nano. 2013 Mar 26;7(3):2099-105 - PubMed
  2. Clin Chem. 1999 May;45(5):630-7 - PubMed
  3. Biomed Opt Express. 2011 Sep 1;2(9):2484-92 - PubMed
  4. Biomed Pharmacother. 2015 Mar;70:19-23 - PubMed
  5. Eur J Cancer. 2001 Feb;37(3):355-63 - PubMed
  6. Cancer Res. 2001 Jun 15;61(12):4744-9 - PubMed
  7. PLoS One. 2012;7(2):e32406 - PubMed
  8. Expert Rev Mol Diagn. 2010 Sep;10(6):787-98 - PubMed
  9. Clin Chem. 1989 Oct;35(10):2152-3 - PubMed
  10. ACS Nano. 2013 Jun 25;7(6):4967-76 - PubMed
  11. CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62 - PubMed
  12. Oncol Rep. 2009 Nov;22(5):1119-27 - PubMed
  13. Clin Cancer Res. 1999 Jun;5(6):1497-502 - PubMed
  14. Anal Chem. 2012 Mar 20;84(6):2837-42 - PubMed
  15. Science. 1997 Feb 21;275(5303):1102-6 - PubMed
  16. CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71 - PubMed
  17. Anal Biochem. 2000 Jul 1;282(2):232-8 - PubMed
  18. Nat Rev Drug Discov. 2006 Apr;5(4):310-20 - PubMed
  19. Nat Rev Clin Oncol. 2013 Jul;10(7):377-89 - PubMed
  20. PLoS One. 2012;7(1):e30887 - PubMed
  21. Ann Oncol. 2008 Apr;19(4):675-81 - PubMed
  22. N Engl J Med. 2013 Mar 28;368(13):1199-209 - PubMed
  23. Nat Biotechnol. 2005 Oct;23(10):1294-301 - PubMed
  24. Breast Cancer. 2003;10(3):220-7 - PubMed
  25. Angew Chem Int Ed Engl. 2014 Dec 15;53(51):14115-9 - PubMed
  26. Chem Soc Rev. 2008 May;37(5):1001-11 - PubMed
  27. Nat Biotechnol. 2013 Jun;31(6):539-44 - PubMed
  28. J Natl Cancer Inst. 2001 Jul 4;93(13):979-89 - PubMed

Publication Types

Grant support